Antonaccio M J, Gomoll A
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000.
Am J Cardiol. 1993 Aug 12;72(4):27A-37A. doi: 10.1016/0002-9149(93)90022-5.
Sotalol is a competitive beta adrenoceptor antagonist devoid of membrane-stabilizing activity and intrinsic sympathomimetic activity that has no preferential actions on beta 1 or beta 2 responses. No other tested receptor systems are affected by sotalol. In addition to having class II (beta blockade) effects, sotalol also has class III antiarrhythmic activity. It increases the action potential duration (APD) and prolongs atrial and ventricular repolarization. The effect on APD is independent of beta blockade; the same effect is seen with similar concentrations of the d stereoisomer of sotalol, which does not have beta-blocking activity. Sotalol prolongs the rate-corrected QT interval and ventricular and atrial refractoriness without affecting atrial, His-Purkinje, or ventricular conduction velocity. Atrioventricular nodal conduction is decreased, largely because of beta blockade. Sotalol increases the fibrillation threshold and decreases the defibrillation threshold. Sotalol is an effective antiarrhythmic in various animal models of arrhythmia (e.g., chloroform, hydrocarbon-catecholamine, ouabain, and coronary ligation). In addition, it reduces the severity and frequency of arrhythmias induced by programmed electrical simulation. By comparison, metoprolol is ineffective and d-sotalol is as effective as the racemate in this model, indicating that this effect is independent of beta blockade. Sotalol causes concentration-dependent increases in the contractility of isolated ventricular tissue that is not blocked by previous beta or alpha blockade or catecholamine depletion. The positive inotropic effect may be related to inhibition of time-dependent K+ current responsible for the increase in APD. Like propranolol, sotalol decreases contractile force, heart rate, arterial blood pressure, left ventricular dP/dt, and cardiac output in intact animals due to blockade of circulating catecholamines. Sotalol consistently reduces the heart rate to a greater degree than propranolol and causes significantly less cardiac suppression than propranolol at a given heart rate.
索他洛尔是一种竞争性β肾上腺素能受体拮抗剂,不具有膜稳定活性和内在拟交感活性,对β1或β2反应无优先作用。索他洛尔不影响其他经测试的受体系统。除具有Ⅱ类(β受体阻滞)作用外,索他洛尔还具有Ⅲ类抗心律失常活性。它可增加动作电位时程(APD),延长心房和心室复极化。对APD的影响与β受体阻滞无关;索他洛尔的d立体异构体浓度相似时也有相同效果,而该异构体不具有β受体阻滞活性。索他洛尔可延长校正心率后的QT间期以及心室和心房不应期,而不影响心房、希氏-浦肯野纤维或心室传导速度。房室结传导减慢,主要是由于β受体阻滞。索他洛尔可提高颤动阈值并降低除颤阈值。在各种心律失常动物模型(如氯仿、烃-儿茶酚胺、哇巴因和冠状动脉结扎)中,索他洛尔都是有效的抗心律失常药物。此外,它还可降低程序电刺激诱发的心律失常的严重程度和频率。相比之下,美托洛尔无效,而在该模型中d-索他洛尔与消旋体一样有效,这表明该作用与β受体阻滞无关。索他洛尔可使离体心室组织的收缩力呈浓度依赖性增加,这种作用不受先前β或α受体阻滞或儿茶酚胺耗竭的影响。正性肌力作用可能与抑制导致APD增加的时间依赖性钾电流有关。与普萘洛尔一样,由于阻断循环中的儿茶酚胺,索他洛尔可降低完整动物的收缩力、心率、动脉血压、左心室dp/dt和心输出量。索他洛尔持续降低心率的程度比普萘洛尔更大,且在给定心率下引起的心脏抑制比普萘洛尔明显更小。